Status:
COMPLETED
Characterization of Hyperparathyroidism and Vitamin D Deficiency in Obesity
Lead Sponsor:
Weill Medical College of Cornell University
Conditions:
Vitamin D Deficiency
Secondary Hyperparathyroidism
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
Obese persons are known to have elevated levels of parathyroid hormone (PTH) and low levels of vitamin D. These hormones are important in regulation of the body's calcium stores and bone health. We wo...
Eligibility Criteria
Inclusion
- Obese subjects with body mass indices greater than 40 kg/m2 or 35 kg/m2 with other medical conditions secondary to obesity
- Willingness to take vitamin D supplements
- If baseline vitamin D level is \>25 ng/ml subjects will be eligible for the control group
- If baseline vitamin D level is \<25 ng/ml subjects will be eligible for one of the two vitamin D replacement groups
Exclusion
- Hypercalcemia
- Kidney disease
- Liver disease
- Malabsorption
- Prior diagnosis of bone disease
- Medical conditions requiring daily use of calcium, antacids, or medications known to affect bone metabolism or interact with vitamin D
- Hypersensitivity to any formulation of vitamin D
Key Trial Info
Start Date :
February 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2007
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00288873
Start Date
February 1 2006
End Date
July 1 2007
Last Update
December 20 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Weill Cornell Medical College
New York, New York, United States, 10021